Personalis PSNL 深 沪
等待开盘 05-18 09:30:00 美东时间
6.36
-0.350
-5.22%
华盛通- 最 高6.59
- 今 开6.52
- 成交量 177.38万股
- 最 低 6.32
- 昨 收 6.71
- 总市值 66.58万
- 52周最高 11.50
- 市盈率 静 --
- 换手率 1694.57%
- 52周最低 3.84
- 委 比 -47.77%
- 总股本 0.00亿
- 历史最高 53.46
- 量 比 0.59
- 振 幅 4.02%
- 历史最低 0.8906
- 每 手 1
- 风险率 1.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多C-Rad and SeeTreat Forge Alliance to Advance Personalised Radiotherapy Workflows
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an announcement. C-Rad AB has en...
05-15 17:19
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
BTIG Maintains Buy on Personalis, Lowers Price Target to $11
BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price target from $13 to $11.
05-11 18:41
新浪财经ESG：Personalis MSCI（明晟）ESG评级调升至A
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
05-01 07:00
Personalis Presents NeXT Personal ctDNA Data At AACR 2026 Showing 100% Sensitivity In Colorectal Cancer Monitoring
Podium presentation on NeXT Personal monitoring neoadjuvant therapy in colorectal cancer;Real-world data from 10,000 patients reinforce industry-leading sensitivity;Data presented for a new NeXT Personal feature for
04-21 18:10
Personalis Showcases New Cancer Test To Track Treatment Resistance In Real Time
Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that an oral podium presentation featuring colorectal cancer data for the company's NeXT Personal ultrasensitive ctDNA
04-13 18:11
Cathie Wood's weekly recap: adds JOBY, CRSP, TEM, sells TER, TXG, CRCL
Cathie Wood’s Ark Invest reshuffled positions across its ETFs during last week, adding positions to gene-editing and AI healthcare names while trimming genomics tools and semiconductor equipment holdi...
03-16 19:05
Personalis Announces The Publication Of PREDICT-DNA Study In The Journal Of Clinical Oncology, Showing That Ultrasensitive Molecular Residual Disease Testing With Next Personal Can Perform Better Than Current Standard Approaches In Predicting Patient Outcomes Following Neoadjuvant Therapy
The prospective study followed 227 patients with Triple-Negative (TNBC) and HER2+ breast cancer across more than 24 leading US cancer centers. The results demonstrate the ability of NeXT Personal to provide a more
03-12 18:57
Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk
Personalis PREDICT-DNA study links post-neoadjuvant ctDNA to 4x-9x higher breast cancer relapse risk Personalis reported results from the prospective PREDICT-DNA study in the Journal of Clinical Oncology evaluating the NeXT Personal ctDNA assay for monitoring molecular residual disease in triple-neg
03-12 18:01
